The pharmacologic management of premenstrual dysphoric disorder

@article{Rapkin2008ThePM,
  title={The pharmacologic management of premenstrual dysphoric disorder},
  author={A. Rapkin and S. Winer},
  journal={Expert Opinion on Pharmacotherapy},
  year={2008},
  volume={9},
  pages={429 - 445}
}
Premenstrual dysphoric disorder (PMDD) is characterized by physical, affective and behavioral symptoms that are linked to the luteal phase of the menstrual cycle and relieved soon after the onset of menses. The disorder is chronic and exerts a major impact on personal relationships and occupational productivity for the estimated 6% of reproductive-aged women who fulfill strict PMDD criteria and the almost 20% of women who nearly meet these criteria. There are now various pharmacologic options… Expand
Diagnosis and management of premenstrual disorders
TLDR
The classification of premenstrual disorders, how to measure symptoms and diagnose the condition, and effective management strategies are discussed. Expand
Menstrual cycle-related exacerbation of disease.
TLDR
Common mental health problems exacerbated by the menstrual cycle are discussed, with a particular focus on premenstrual dysphoric disorder and perimenopausal depression. Expand
The Role of Reproductive Psychiatry in Women’s Mental Health
TLDR
This chapter describes the emerging field of reproductive psychiatry, including training programs, opportunities for continuing education, and the basics of screening and assessment, and highlights the clinical, ethical, and legal challenges of psychopharmacology in women’s mental health, particularly in pregnant or breastfeeding women. Expand
[Involvement of some subtypes of 5-HT2-receptors in affective behavior in female rats].
TLDR
The data obtained indicate a close interaction between the ovary hormonal and serotonergic systems of the brain in the mechanisms of anxiety and depression. Expand
Target-based biomarker selection - Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression.
TLDR
In conclusion, correlates of higher central MR-activation are associated with poorer clinical improvement, particularly in men, which contrasts with the finding of a peripheral MR-desensitization in more refractory patients. Expand
What Are Women Being Exposed to? A Review of the Quality, Content and Ownership of Websites on Premenstrual Dysphoric Disorder.
  • C. Hardy, Elizabeth Sillence
  • Psychology, Medicine
  • Women's health issues : official publication of the Jacobs Institute of Women's Health
  • 2016
TLDR
The paper presents the five highest scoring websites that may be used by those with a vested interest in PM DD, such as health professionals or women with PMDD, to address this gap by reviewing websites containing PMDD information. Expand
Effects of 8-OH-DPAT and NAN-190 on anxiety behavior, monoamine metabolism, and the level of sex hormones in female rats during the estrus cycle
In this study, we performed a comparative analysis of the effects of chronic administration of an agonist of 5-HT1A receptors, 8-OH-DPAT, (0.05 mg/kg, subcutaneously) and an antagonist of 5-HT1AExpand
Effects of 8-OH-DPAT and NAN-190 on Anxious-Depressive-Like Behavior of Female Rats during the Estrous Cycle
TLDR
Administration of 8-OH-DPAT had no effect on anxiety level, but produced a pronounced antidepressive effect irrespective of the phase of the estrous cycle, as well as chronic administration of NAN-190 during the estrus phase, which produced an anxiogenic effect. Expand
Premenstrual disphoric disorder: an update
...
1
2
...

References

SHOWING 1-10 OF 146 REFERENCES
Fluoxetine in the Treatment of Premenstrual Dysphoria
TLDR
This study evaluated the efficacy and safety of fluoxetine (which selectively inhibits the reuptake of serotonin) in the treatment of premenstrual dysphoria and found it to be safe and effective. Expand
Symptom-Onset Treatment for Women with Premenstrual Dysphoric Disorder
TLDR
The need to further evaluate symptom-onset treatment in a larger randomized clinical trial is suggested, as many women have less than a week of symptoms, and shorter treatment intervals would further reduce medication exposure and costs. Expand
Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.
TLDR
Luteal phase treatment in women with dysphoric PMS produced significant improvements in depression, impairment, and global ratings compared with placebo and was equivalent in efficacy to sertraline given during the entire menstrual cycle. Expand
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
TLDR
Drospirenone/EE, given in a 24/4 regimen, was superior to placebo for improving symptoms associated with PMDD. Expand
Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment: A Randomized Controlled Trial
TLDR
Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment. Expand
Placebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual Dysphoric Disorder
TLDR
It is indicated that the response rate when treating PMDD with SRIs is high, and that irritability is a key target symptom, and intermittent treatment was as effective as continuous treatment in reducing irritability, affect lability, and mood swings. Expand
Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder
TLDR
Venlafaxine was significantly more effective than placebo in reducing PMDD symptoms as assessed by DSR scores and was significantly better than placebo for all statistically derived DSR factors (mood, function, pain, and physical symptoms). Expand
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
TLDR
A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 &mgr;g improves symptoms associated with premenstrual dysphoric disorder. Expand
Diagnosis of premenstrual disorders.
TLDR
Diagnostic criteria for premenstrual syndrome (PMS) and dysphoric disorder (PMDD) were published by the American College of Obstetricians and Gynecologists in 2000; the American Psychiatric Association had previously established very specific diagnostic criteria for PMDD. Expand
Treatment of premenstrual syndrome with gonadotropin‐releasing hormone agonist in a low dose regimen
TLDR
Premenstrual irritability and depression were significantly relieved by low dose GnRH agonist, and GnRH treatment significantly reduced premenstrual depression and irritability, however, low doses GnRH therapy is prone to induce anovulation, particularly with increasing age. Expand
...
1
2
3
4
5
...